- Home
- AGX vs PTGX Comparison
AGX vs PTGX Comparison
Compare AGX & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGX
- PTGX
- Stock Information
- Founded
- AGX 1961
- PTGX 2006
- Country
- AGX United States
- PTGX United States
- Employees
- AGX N/A
- PTGX N/A
- Industry
- AGX Engineering & Construction
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- AGX Consumer Discretionary
- PTGX Health Care
- Exchange
- AGX Nasdaq
- PTGX Nasdaq
- Market Cap
- AGX 3.0B
- PTGX 3.3B
- IPO Year
- AGX N/A
- PTGX 2016
- Fundamental
- Price
- AGX $235.73
- PTGX $55.15
- Analyst Decision
- AGX Buy
- PTGX Strong Buy
- Analyst Count
- AGX 3
- PTGX 9
- Target Price
- AGX $202.00
- PTGX $67.11
- AVG Volume (30 Days)
- AGX 422.8K
- PTGX 790.5K
- Earning Date
- AGX 09-04-2025
- PTGX 08-05-2025
- Dividend Yield
- AGX 0.64%
- PTGX N/A
- EPS Growth
- AGX 154.06
- PTGX N/A
- EPS
- AGX 7.14
- PTGX 0.86
- Revenue
- AGX $910,157,000.00
- PTGX $207,801,000.00
- Revenue This Year
- AGX $10.87
- PTGX N/A
- Revenue Next Year
- AGX $18.35
- PTGX $53.09
- P/E Ratio
- AGX $33.02
- PTGX $63.95
- Revenue Growth
- AGX 45.08
- PTGX N/A
- 52 Week Low
- AGX $63.53
- PTGX $32.50
- 52 Week High
- AGX $246.60
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- AGX 65.28
- PTGX 56.72
- Support Level
- AGX $196.90
- PTGX $51.55
- Resistance Level
- AGX $228.04
- PTGX $57.73
- Average True Range (ATR)
- AGX 10.95
- PTGX 1.74
- MACD
- AGX 1.56
- PTGX -0.07
- Stochastic Oscillator
- AGX 90.32
- PTGX 69.13
About AGX Argan Inc.
Argan Inc is a United States-based construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC, and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Telecom Services, out of which Power Services derives the majority of revenue.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.